We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Idera Announces Publication of Studies on Chemistry of Novel Antagonists for Toll-like Receptors 7 and 9
News

Idera Announces Publication of Studies on Chemistry of Novel Antagonists for Toll-like Receptors 7 and 9

Idera Announces Publication of Studies on Chemistry of Novel Antagonists for Toll-like Receptors 7 and 9
News

Idera Announces Publication of Studies on Chemistry of Novel Antagonists for Toll-like Receptors 7 and 9

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Idera Announces Publication of Studies on Chemistry of Novel Antagonists for Toll-like Receptors 7 and 9"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Idera Pharmaceuticals, Inc. has announced the publication of studies on the chemistry of novel compounds that have been shown to act as antagonists for Toll-like Receptors (TLR) 7 and 9. These antagonist candidates have potential application in autoimmune and inflammatory diseases.

The paper entitled “Oligodeoxyribonucleotide-Based Antagonists for Toll-Like Receptors 7 and 9” is published in the Journal of Medicinal Chemistry and is authored by Daqing Wang, Ph.D., Lakshmi Bhagat, Ph.D., Dong Yu, Ph.D., Fu-Gang Zhu, Ph.D., Jimmy Tang, M.S., Ekambar Kandimalla, Ph.D., and Sudhir Agrawal, D.Phil., all of Idera.

“These novel antagonist candidates have been created through our ongoing structure-activity relationship studies of oligonucleotides, through which we have also identified agonists of TLR7, 8 and 9,” said Sudhir Agrawal, D.Phil., Chief Executive Officer and Chief Scientific Officer. “We have evaluated selected antagonist candidates in preclinical models of lupus, rheumatoid arthritis, multiple sclerosis, psoriasis, and colitis, and studies continue in additional preclinical models of autoimmune and inflammatory diseases.”

“Based on encouraging results in preclinical models, we are conducting preclinical development studies with our lead TLR antagonist drug candidate, IMO-3100, for an intended Investigational New Drug application,” said Tim Sullivan, Ph.D., Vice President of Development Programs.

“Members of our Autoimmune Disease Scientific Advisory Board are assisting us in the clinical development strategy for IMO-3100 and other antagonist candidates in autoimmune and inflammatory diseases,” Sullivan added.
Advertisement